VanEck Pharmaceutical ETF

US Public Saves up to 85% on Pfizer Medications via TrumpRx

Novo Nordisk plans to hold its Annual General Meeting on March 26, 2026

Competitor Eli Lilly's oral weight-loss drug expects key FDA review decision on April 10

Novo Nordisk's star oral weight-loss drug Wegovy surpasses 38,000 prescriptions in its fifth week post-launch

Eli Lilly and Tsinghua University launch a creative competition for Alzheimer's disease awareness

IQVIA data shows Novo Nordisk's Wegovy tablet prescriptions at 38,909

Novo Nordisk declares dividend with ex-dividend date of March 30, 2026

Market awaits FDA decision on high-dose Wegovy this quarter

Semaglutide ameliorates osteoarthritis progression

Bernstein Raises Astrazeneca Target Price to 20,500 Pence

Dutch city of Katwijk is overjoyed and concerned by the arrival of a $3 billion Eli Lilly factory.

Novartis' Phase III ALIGN Study Shows Vanrafia Slows Kidney Function Decline in IgAN Patients

AstraZeneca Reports Positive Results from Breztri Aerosphere Phase III Clinical Trials

Eli Lilly's new drug Mirikizumab approved for marketing in China

Data shows Novo Nordisk's oral weight-loss drug successfully attracted over 30% new patients

AlphaValue/Baader Cuts Novo Nordisk's Target Price and Forecast

Performance of Medical Innovation ETF and Medical Device Innovation Index Constituents

Eli Lilly Announces Acquisition of Orna Therapeutics to Expand into RNA Therapies

Analysis brands Novo Nordisk the 'Ugly' performer of the Big Pharma earnings season

Eli Lilly's Acquisition of Ventyx Biosciences Receives Early Termination Notice

Moolec Science SA

Founder

Jiade

Nuveen Real Asset Income and Growth Fund

Corsair Gaming

Atomera

GraniteShares 2x Long RIVN Daily ETF

BUUU

Proshares Ultra COIN

Cooper-Standard

Pinned News

置顶新闻

Cosmos Health CEO Grigorios Siokas Acquires Common Shares

COSM

ARKG

SBIO

Grigorios Siokas, CEO of Cosmos Health Inc., has acquired common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. Cosmos Health Inc. is responsible for the original content published via EDGAR on February 13, 2026.

PUBT

Cosmos Health

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Pharma

iShares Biotechnology ETF

SPDR Pharmac

SPDR S&P Health Equip

iShares US Medical Devices

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Invesco Pharmaceuticals ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

IBBQ

Novartis announced promising final Phase 3 results for its kidney drug Vanrafia, indicating it may slow kidney function decline in adults with IgA nephropathy. The drug received accelerated approval in the U.S. and China in April 2025 for reducing proteinuria. Novartis plans to seek traditional approval in 2026 based on ongoing studies. The ALIGN study showed a significant difference in estimated glomerular filtration rate (eGFR) change compared to placebo, with safety findings consistent with previous data. Novartis shares rose 0.42% to $161.86 in premarket trading, nearing a 52-week high.

benzinga_article

Invesco Nasdaq Biotechnology ETF

Novartis AG

iShares Global Healthcare

NOVARTIS AG

Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise

AlphaValue/Baader Europe Cuts Novo Nordisk Price Target, Forecasts Amid Outlook Downgrades, Competitive Pressures

marketscreener

Novo Nordisk AS

AlphaValue/Baader Europe Cuts Novo Nordisk Price Target, Forecasts Amid Outlook Downgrades, Competitive Pressures

Biocon aims for high double-digit revenue growth with the global launch of generic weight-loss drugs, including versions of Novo Nordisk’s Wegovy and liraglutide. The company plans to launch liraglutide in the U.S. in the next financial year and Wegovy in Canada, while being cautious about entering the Indian market due to intense price competition and regulatory hurdles. The global obesity medicines market is projected to reach $150 billion by the early 2030s, with generics expected to be priced significantly lower than original products. Biocon's revenue grew 5.4% in fiscal 2025, with higher quarter-on-quarter growth.

Reuters

Biocon aims for revenue surge with rollout of generic weight-loss drugs

Shares of Hims & Hers Healthfell 4% to $16.01, marking the company's tenth consecutive day of losses. This decline follows the announcement of a $49 compounded version of Novo Nordisk’s Wegovy pill for weight loss, which was later withdrawn due to regulatory scrutiny. Additionally, HIMS faces a lawsuit from Novo for patent infringement related to semaglutide, the active ingredient in Wegovy. Year-to-date, HIMS shares have decreased by 50%.

SPDR S&P Health

Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

iShares US Healthcare Providers

BUZZ-Hims & Hers falls, set for tenth straight day of losses

MDGL

NVOX

Madrigal Pharmaceuticals has entered a $4.4 billion licensing deal with Suzhou Ribo Life Science to expand its MASH pipeline, focusing on metabolic dysfunction-associated steatohepatitis (MASH). The agreement includes a $60 million upfront payment for rights to six preclinical siRNA therapies aimed at silencing disease-causing genes. Madrigal's Rezdiffra, the first approved treatment for MASH, may be combined with these new therapies. The MASH market is projected to grow significantly, with Rezdiffra's sales expected to reach $6.9 billion by 2032, despite competition from Novo Nordisk's Wegovy.

Pharmaceutical Technology

Madrigal Pharma

Defiance Daily Target 2X Long NVO ETF

Direxion S&P Biotech Bear 3X

Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal

MSD has received FDA approval for Keytruda and Keytruda Qlex, in combination with paclitaxel, for treating platinum-resistant ovarian cancer. This approval is based on Phase III KEYNOTE-B96 trial data, showing significant improvements in progression-free and overall survival for patients with PD-L1 expressing tumors. The therapies are intended for adults with limited treatment options, marking a significant advancement in ovarian cancer treatment.

Merck

MSD receives FDA approval for Keytruda combo to treat ovarian cancer

AnaptysBio (NASDAQ:ANAB) plans to separate its royalty business from its clinical-stage biopharma operations, targeting completion in Q2. The split aims to align capital needs, with the royalty entity focused on cash returns and the biopharma company advancing clinical programs. The company has $310 million in cash, with plans to fund the biopharma unit through 2027. Key revenue drivers include GSK’s Jemperli, which saw Q4 sales of $343 million, and ANB033 for celiac disease, with data expected in Q4 2023.

Market Beat

Anaptysbio

GlaxoSmithKline plc

AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4

Novo Nordisk to Manufacture Wegovy in Ireland Facility

Novo Nordisk to Manufacture Wegovy in Ireland Facility

GS-D

GS-C

The Dow Jones Index is falling -124 points.Losses were driven by Nvidia (-2.34%), Goldman Sachs (-1.82%) and 3M (-1.63%).Biggest rises came from Salesforce (2.63%), Nike (2.59%) and Merck (2.17%).

Trading Economics

Nike

GOLDMAN SACHS GROUP INC DEP REP 1/1000TH PRF D

GOLDMAN SACHS GROUP INC DEP SHS REPSTG 1/1000TH PRF SER C

GOLDMAN SACHS GROUP INC DEP SHR REP 1/1000TH PFD SER A

Goldman Sachs

Salesforce

First Trust Nasdaq Food & Semicon

Leverage Shares 2X Long CRM Daily ETF

Financial Select Sector SPDR Fund

Direxion Daily NVDA Bull 2X Shares

ISHRS S&P Glb It

VG Financial

ISHRS Us Brokers & Sec Exchg

VanEck Semiconductor ETF

Spdr Select Tech

GraniteShares 2x Long NVDA Daily ETF

iShares Semiconductor ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

Direxion Semicon Bull 3X

SPDR S&P Semicon

T-Rex 2X Long NVIDIA Daily Target ETF

Invesco Semiconductors ETF

YieldMax NVDA Option Income Strategy ETF

NVIDIA

The Dow Jones Index Opens 0.25% Lower

Novo set to make Wegovy pill in Ireland for markets outside US - Bloomberg News

Novo set to make Wegovy pill in Ireland for markets outside US - Bloomberg News

ELIL

Novo Nordisk plans to launch Wegovy in vials, exploring various device presentations, with some launching this year. Currently, Wegovy is available in injectable and oral forms. This move comes as competition intensifies with Eli Lilly, which began selling vials of its weight-loss drug Zepbound in 2024, after cutting prices and expanding doses. Novo aims to regain its position in the obesity-drug market after Zepbound surpassed Wegovy in U.S. prescriptions last year.

Eli Lilly

Direxion Daily LLY Bull 2X Shares

Novo Nordisk plans to launch Wegovy vials

NOVO NORDISK AIMS TO START SELLING ITS WEIGHT-LOSS BLOCKBUSTER WEGOVY IN VIALS - BLOOMBERG NEWS

Novo Nordisk Aims To Start Selling Its Weight-Loss Blockbuster Wegovy In Vials - Bloomberg News

Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00. Holford, a 4-star analyst with a 59.14% success rate, focuses on the Healthcare sector. Recently, Deutsche Bank also issued a Buy rating for Novo Nordisk, while Barclays maintained a Hold rating on February 9.

Tip Ranks

Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Merck announced that the U.S. FDA has approved KEYTRUDA (pembrolizumab and berahyaluronidase alfa-pmph) for treating adults with PD-L1+ platinum-resistant ovarian cancer, following one or two prior treatments. Additionally, KEYTRUDA and KEYTRUDA QLEX are approved for first-line treatment of adults with HER2-positive gastric or gastroesophageal junction adenocarcinoma, in combination with chemotherapy, for tumors expressing PD-L1 (CPS 1). These approvals are significant for the ovarian cancer community and reflect Merck's investment in KEYTRUDA.

Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX

The FDA has approved Merck's KEYTRUDA regimen for treating adults with PD-L1 positive platinum-resistant ovarian cancer. This includes KEYTRUDA® and KEYTRUDA QLEX™ in combination with paclitaxel, with or without bevacizumab, for patients who have undergone one or two prior treatments. The approval is based on the Phase 3 KEYNOTE-B96/ENGOT-ov65 trial data, conducted with ENGOT groups. Merck is responsible for the original content published via Business Wire.

FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer

VanEck Pharmaceutical ETF(PPH.US)

Cosmos Health CEO Grigorios Siokas Acquires Common Shares

Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise

AlphaValue/Baader Europe Cuts Novo Nordisk Price Target, Forecasts Amid Outlook Downgrades, Competitive Pressures

Biocon aims for revenue surge with rollout of generic weight-loss drugs

BUZZ-Hims & Hers falls, set for tenth straight day of losses